FASN and cholangiocarcinoma: In parallel, metabolic signatures involving glycolysis (e.g., LDHA), FAO/lipogenesis (e.g., FASN, SCD1) and mitochondrial dysfunction (e.g., an OXPHOS gene set) correlate strongly with adverse clinical features in intrahepatic CCA (iCCA).